Sort   by:  
 Page size 
UnknownRapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.
Not available
S-EPMC7334099 | biostudies-literature
UnknownTumor immunogenomic signatures improve a prognostic model of melanoma survival.
Not available
S-EPMC7888085 | biostudies-literature
UnknownC reactive protein impairs adaptive immunity in immune cells of patients with melanoma.
Not available
S-EPMC7204799 | biostudies-literature
UnknownClinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
Not available
S-EPMC9444873 | biostudies-literature
UnknownGut microbiome is associated with recurrence-free survival in patients with resected Stage IIIB-D or Stage IV melanoma treated with immune checkpoint inhibitors.
Not available
S-EPMC11042335 | biostudies-literature
UnknownTyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
Not available
S-EPMC12269477 | biostudies-literature
UnknownBacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Not available
S-EPMC8513370 | biostudies-literature
UnknownThe complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients.
Not available
S-EPMC6700794 | biostudies-literature
UnknownUsing Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.
Not available
S-EPMC7785656 | biostudies-literature
UnknownGermline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Not available
S-EPMC11000635 | biostudies-literature
Sort   by:  
 Page size